Julian Blanco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3460787/publications.pdf

Version: 2024-02-01

210 papers	8,762 citations	36303 51 h-index	60623 81 g-index
227 all docs	227 docs citations	227 times ranked	11152 citing authors

#	Article	IF	Citations
1	Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins. Journal of Infectious Diseases, 2022, 225, 938-946.	4.0	26
2	Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells. PLoS Pathogens, 2022, 18, e1010171.	4.7	18
3	Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports, 2022, 12, 640.	3.3	11
4	Small form factor flow virometer for SARS-CoV-2. Biomedical Optics Express, 2022, 13, 1609.	2.9	3
5	Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection. Cell Reports Medicine, 2022, 3, 100523.	6.5	18
6	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 278-288.	10.7	61
7	Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1. Plant Cell Reports, 2022, , 1.	5.6	3
8	Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. International Journal of Molecular Sciences, 2022, 23, 2202.	4.1	3
9	The Characteristics of the HIV-1 Env Glycoprotein Are Linked With Viral Pathogenesis. Frontiers in Microbiology, 2022, 13, 763039.	3.5	7
10	HIV-1 trans-Infection Mediated by DCs: The Tip of the Iceberg of Cell-to-Cell Viral Transmission. Pathogens, 2022, 11, 39.	2.8	4
11	Chronological brain lesions after SARS-CoV-2 infection in hACE2-transgenic mice. Veterinary Pathology, 2022, 59, 613-626.	1.7	37
12	Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities. Age and Ageing, 2022, 51, .	1.6	7
13	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nature Communications, 2022, 13, 2583.	12.8	25
14	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. Frontiers in Immunology, 2022, 13, .	4.8	2
15	Heterogeneous Infectivity and Pathogenesis of SARS-CoV-2 Variants Beta, Delta and Omicron in Transgenic K18-hACE2 and Wildtype Mice. Frontiers in Microbiology, 2022, 13, .	3.5	39
16	Performance of SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Tests for Omicron and Other Variants of Concern. Frontiers in Microbiology, 2022, 13, .	3.5	15
17	Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Frontiers in Immunology, 2022, 13, 860215.	4.8	6
18	Transactive Response DNA-Binding Protein (TARDBP/TDP-43) Regulates Cell Permissivity to HIV-1 Infection by Acting on HDAC6. International Journal of Molecular Sciences, 2022, 23, 6180.	4.1	6

#	Article	IF	Citations
19	Pigs are not susceptible to SARSâ€CoVâ€2 infection but are a model for viral immunogenicity studies. Transboundary and Emerging Diseases, 2021, 68, 1721-1725.	3.0	51
20	Impact of HIV infection on aging and immune status. Expert Review of Anti-Infective Therapy, 2021, 19, 719-731.	4.4	10
21	Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochemical and Biophysical Research Communications, 2021, 538, 187-191.	2.1	86
22	SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Scientific Reports, 2021, 11, 2608.	3.3	86
23	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Frontiers in Pharmacology, 2021, 12, 646676.	3.5	40
24	Stable neutralizing antibody levels 6Âmonths after mild and severe COVID-19 episodes. Med, 2021, 2, 313-320.e4.	4.4	77
25	The Interplay of HIV and Autophagy in Early Infection. Frontiers in Microbiology, 2021, 12, 661446.	3.5	20
26	Influence of the Antiretroviral Regimen on the Early Changes in Plasma HIV RNA and Immune Activation at Initiation of Antiretroviral Therapy in NaÃ¯ve HIV-1â€“Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e146-e149.	2.1	0
27	Autoimmune B Cell Repertoire in a Mouse Model of SjÃ¶grenâ€™s Syndrome. Frontiers in Immunology, 2021, 12, 666545.	4.8	6
28	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	3.3	17
29	Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report. Open Forum Infectious Diseases, 2021, 8, ofab329.	0.9	7
30	Mouthwashes with CPC Reduce the Infectivity of SARS-CoV-2 Variants In Vitro. Journal of Dental Research, 2021, 100, 1265-1272.	5.2	49
31	Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses. Nature Communications, 2021, 12, 4740.	12.8	104
32	Monitoring Natural SARS-CoV-2 Infection in Lions (Panthera leo) at the Barcelona Zoo: Viral Dynamics and Host Responses. Viruses, 2021, 13, 1683.	3.3	51
33	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes, 2021, 11, 64.	3.0	0
34	Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster. Emerging Microbes and Infections, 2021, 10, 797-809.	6.5	42
35	SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells. Cellular and Molecular Immunology, 2021, 18, 2676-2678.	10.5	36
36	DBP rs7041 and DHCR7 rs3829251 are Linked to CD4+ Recovery in HIV Patients on Antiretroviral Therapy. Frontiers in Pharmacology, 2021, 12, 773848.	3.5	0

#	Article	IF	Citations
37	First Detection of SARS-CoV-2 Delta (B.1.617.2) Variant of Concern in a Dog with Clinical Signs in Spain. Viruses, 2021, 13, 2526.	3.3	20
38	Extremely low viral reservoir in treated chronically HIV-1-infected individuals. EBioMedicine, 2020, 57, 102830.	6.1	18
39	TL1Aâ€“DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1â€“Specific T Cell Responses. Journal of Immunology, 2020, 205, 3348-3357.	0.8	3
40	Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery. Frontiers in Immunology, 2020, 11, 582330.	4.8	4
41	Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. PLoS Pathogens, 2020, 16, e1008678.	4.7	25
42	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE, 2020, 15, e0238575.	2.5	3
43	Detection of SARS-CoV-2 in a cat owned by a COVID-19â˜affected patient in Spain. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24790-24793.	7.1	154
44	Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations. Polymers, 2020, 12, 2392.	4.5	0
45	Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. Annals of Oncology, 2020, 31, 978-990.	1.2	87
46	New signatures of poor CD4 cell recovery after suppressive antiretroviral therapy in HIV-1-infected individuals: involvement of miR-192, IL-6, sCD14 and miR-144. Scientific Reports, 2020, 10, 2937.	3.3	14
47	Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection. JAMA Oncology, 2020, 6, 1063.	7.1	70
48	Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. Journal of Hepatology, 2020, 73, 328-341.	3.7	82
49	Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1â€“positive individuals. PLoS ONE, 2020, 15, e0230772.	2.5	7
50	A Longitudinal Analysis Reveals Early Activation and Late Alterations in B Cells During Primary HIV Infection in Mozambican Adults. Frontiers in Immunology, 2020, 11, 614319.	4.8	0
51	Title is missing!. , 2020, 15, e0238575.		0
52	Title is missing!. , 2020, 15, e0238575.		0
53	Title is missing!. , 2020, 15, e0238575.		0
54	Title is missing!. , 2020, 15, e0238575.		0

#	Article	IF	Citations
55	CD4 recovery is associated with genetic variation in IFNÎ³ and IL19 genes. Antiviral Research, 2019, 170, 104577.	4.1	7
56	Production of HIV-1-based virus-like particles for vaccination: achievements and limits. Applied Microbiology and Biotechnology, 2019, 103, 7367-7384.	3.6	30
57	IL7RA rs6897932 Polymorphism is Associated with Better CD4+ T-Cell Recovery in HIV Infected Patients Starting Combination Antiretroviral Therapy. Biomolecules, 2019, 9, 233.	4.0	9
58	Different pattern of stool and plasma gastrointestinal damage biomarkers during primary and chronic HIV infection. PLoS ONE, 2019, 14, e0218000.	2.5	11
59	Evolution of the gut microbiome following acute HIV-1 infection. Microbiome, 2019, 7, 73.	11.1	69
60	HIV-1 envelope glycoproteins isolated from Viremic Non-Progressor individuals are fully functional and cytopathic. Scientific Reports, 2019, 9, 5544.	3.3	17
61	Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patients. Clinical Science, 2019, 133, 997-1010.	4.3	21
62	Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC. OncoImmunology, 2019, 8, 1602460.	4.6	22
63	Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression. PLoS ONE, 2019, 14, e0214421.	2.5	11
64	New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO Open, 2019, 4, e000684.	4.5	20
65	HIV-1 Nef Targets HDAC6 to Assure Viral Production and Virus Infection. Frontiers in Microbiology, 2019, 10, 2437.	3.5	13
66	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunology, 2019, 12, 232-246.	6.0	56
67	Switching From a Protease Inhibitorâ€“based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapyâ€“suppressed Human Immunodeficiency Virusâ€“infected Individuals. Clinical Infectious Diseases, 2019, 69, 1320-1328.	5.8	23
68	Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.. Journal of Clinical Oncology, 2019, 37, 2501-2501.	1.6	14
69	Myalgic Encephalomyelitis/Chronic Fatigue Syndrome â€“ Evidence for an autoimmune disease. Autoimmunity Reviews, 2018, 17, 601-609.	5.8	199
70	Viral Characteristics Associated with the Clinical Nonprogressor Phenotype Are Inherited by Viruses from a Cluster of HIV-1 Elite Controllers. MBio, 2018, 9, .	4.1	37
71	A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients. Aids, 2018, 32, 565-573.	2.2	26
72	Memory B cell dysregulation in HIV-1-infected individuals. Aids, 2018, 32, 149-160.	2.2	11

#	Article	IF	Citations
73	Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy. Journal of Translational Medicine, 2018, 16, 343.	4.4	6
74	Secreted IgD Amplifies Humoral T Helper 2 Cell Responses by Binding Basophils via Galectin-9 and CD44. Immunity, 2018, 49, 709-724.e8.	14.3	60
75	Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies. Frontiers in Immunology, 2018, 9, 2429.	4.8	15
76	Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. Journal of Antimicrobial Chemotherapy, 2018, 73, 1940-1948.	3.0	19
77	Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7854-E7862.	7.1	28
78	Autophagy and HIV Infection. , 2018, , 145-151.		0
79	Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif. Scientific Reports, 2017, 7, 40800.	3.3	12
80	A Cytokine Pattern That Differentiates Preseroconversion From Postseroconversion Phases of Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 459-466.	2.1	19
81	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 201-205.	2.1	7
82	Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals. Journal of Antimicrobial Chemotherapy, 2017, 72, 2049-2054.	3.0	7
83	Higher levels of IL-6, CD4 turnover and Treg frequency are already present before cART in HIV-infected subjects with later low CD4 recovery. Antiviral Research, 2017, 142, 76-82.	4.1	22
84	Interferon-Î³â€“Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings. Clinical Infectious Diseases, 2017, 65, 1670-1675.	5.8	22
85	Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery. Scientific Reports, 2017, 7, 11711.	3.3	12
86	IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings. Scientific Reports, 2017, 7, 8104.	3.3	26
87	Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. Frontiers in Immunology, 2017, 8, 1154.	4.8	30
88	Aging in HIV-Infected Subjects: A New Scenario and a New View. BioMed Research International, 2017, 2017, 1-9.	1.9	56
89	Elevated humoral response to cytomegalovirus in HIV-infected individuals with poor CD4+ T-cell immune recovery. PLoS ONE, 2017, 12, e0184433.	2.5	17
90	The European ME/CFS Biomarker Landscape project: an initiative of the European network EUROMENE. Journal of Translational Medicine, 2017, 15, 162.	4.4	36

#	Article	IF	Citations
91	Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults. Frontiers in Immunology, 2017, 8, 1925.	4.8	23
92	Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS ONE, 2017, 12, e0184929.	2.5	13
93	Human endogenous retroviruses and cancer. Cancer Biology and Medicine, 2016, 13, 483.	3.0	78
94	Lack of concordance between residual viremia and viral variants driving de novo infection of CD4+ T cells on ART. Retrovirology, 2016, 13, 51.	2.0	14
95	Antiretroviral therapy suppressed participants with low CD4+ T-cell counts segregate according to opposite immunological phenotypes. Aids, 2016, 30, 2275-2287.	2.2	10
96	Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine, 2016, 5, 135-146.	6.1	328
97	Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4⁺T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2016, 213, 1008-1012.	4.0	36
98	Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery. Journal of Translational Medicine, 2015, 13, 230.	4.4	33
99	Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-NaÃ¯ve Chronically HIV-1 Infected Individuals. PLoS ONE, 2015, 10, e0120648.	2.5	5
100	Autophagy and HIV Infection. , 2015, , 1-7.		0
101	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	2.2	21
102	Rapid HIV Progression During Acute HIV-1 Subtype C Infection in a Mozambican Patient with Atypical Seroconversion. American Journal of Tropical Medicine and Hygiene, 2015, 92, 681-683.	1.4	2
103	Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1. Journal of Antimicrobial Chemotherapy, 2015, 70, 1833-1842.	3.0	56
104	Different Plasma Markers of Inflammation Are Influenced by Immune Recovery and cART Composition or Intensification in Treated HIV Infected Individuals. PLoS ONE, 2014, 9, e114142.	2.5	27
105	The effect of cell subset isolation method on gene expression in leukocytes. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2014, 85, 94-104.	1.5	63
106	Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals. Retrovirology, 2014, 11, 44.	2.0	19
107	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. Aids, 2014, 28, 325-334.	2.2	62
108	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. PLoS ONE, 2014, 9, e87334.	2.5	15

#	Article	IF	Citations
109	Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. Journal of Translational Medicine, 2013, 11, 68.	4.4	92
110	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine, 2013, 11, 48.	4.4	3
111	The infectious synapse formed between mature dendritic cells and CD4+T cells is independent of the presence of the HIV-1 envelope glycoprotein. Retrovirology, 2013, 10, 42.	2.0	38
112	Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 648-658.	1.5	13
113	Differential gene expression in HIV-infected individuals following ART. Antiviral Research, 2013, 100, 420-428.	4.1	32
114	Generation of HIV-1 Gag VLPs by transient transfection of HEK 293 suspension cell cultures using an optimized animal-derived component free medium. Journal of Biotechnology, 2013, 166, 152-165.	3.8	99
115	Child cured of HIV: can this be repeated?. Expert Opinion on Pharmacotherapy, 2013, 14, 2307-2309.	1.8	3
116	Attacking the HIV Reservoir from the Immune and Viral Perspective. Current HIV/AIDS Reports, 2013, 10, 33-41.	3.1	15
117	Learning from drug changes in antiretroviral therapy. Aids, 2013, 27, 833-834.	2.2	7
118	Dynamics of CD8 T-Cell Activation After Discontinuation of HIV Treatment Intensification. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 152-160.	2.1	21
119	Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2358-2362.	3.0	28
120	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. Aids, 2013, 27, 1375-1385.	2.2	15
121	Immunodiscordant responses to HAART â€“ mechanisms and consequences. Expert Review of Clinical Immunology, 2013, 9, 1135-1149.	3.0	79
122	HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization. PLoS ONE, 2013, 8, e67085.	2.5	12
123	Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study. Antiviral Therapy, 2012, 17, 355-364.	1.0	108
124	Evaluation of the Cytopathicity (Fusion/Hemifusion) of Patient-Derived HIV-1 Envelope Glycoproteins Comparing Two Effector Cell Lines. Journal of Biomolecular Screening, 2012, 17, 727-737.	2.6	9
125	Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. Aids, 2012, 26, 2285-2293.	2.2	44
126	Viremic HIV Infected Individuals with High CD4 T Cells and Functional Envelope Proteins Show Anti-gp41 Antibodies with Unique Specificity and Function. PLoS ONE, 2012, 7, e30330.	2.5	13

#	Article	IF	Citations
127	Generation and Characterization of a Defective HIV-1 Virus as an Immunogen for a Therapeutic Vaccine. PLoS ONE, 2012, 7, e48848.	2.5	10
128	The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype. Retrovirology, 2012, 9, 15.	2.0	8
129	Susceptibility of Human Lymphoid Tissue Cultured ex vivo to Xenotropic Murine Leukemia Virus-Related Virus (XMRV) Infection. PLoS ONE, 2012, 7, e37415.	2.5	2
130	Adenosine Deaminase Enhances the Immunogenicity of Human Dendritic Cells from Healthy and HIV-Infected Individuals. PLoS ONE, 2012, 7, e51287.	2.5	21
131	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	3.8	38
132	Exosomes and retroviruses: the chicken or the egg?. Cellular Microbiology, 2011, 13, 10-17.	2.1	71
133	The reconstitution of the thymus in immunosuppressed individuals restores CD4â€specific cellular and humoral immune responses. Immunology, 2011, 133, 318-328.	4.4	12
134	Dynamic Imaging of Cellâ€Free and Cellâ€Associated Viral Capture in Mature Dendritic Cells. Traffic, 2011, 12, 1702-1713.	2.7	32
135	Viral infection. Communicative and Integrative Biology, 2011, 4, 398-408.	1.4	7
136	Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART. PLoS Pathogens, 2011, 7, e1002314.	4.7	55
137	HIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes. Molecular Biology of the Cell, 2011, 22, 1148-1166.	2.1	47
138	Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. Journal of Clinical Investigation, 2011, 121, 2391-2400.	8.2	168
139	Viral infection: Moving through complex and dynamic cell-membrane structures. Communicative and Integrative Biology, 2011, 4, 398-408.	1.4	5
140	Hot Immunological Topics in HIV Infection. Journal of AIDS & Clinical Research, 2011, 02, .	0.5	9
141	Changes in T-cell subsets in HIVâ€“HCV-coinfected patients during pegylated interferon-Î±2a plus ribavirin treatment. Antiviral Therapy, 2010, 15, 333-342.	1.0	16
142	Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir. Antiviral Therapy, 2010, 15, 431-436.	1.0	2
143	HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nature Medicine, 2010, 16, 460-465.	30.7	500
144	Nadir CD4 T Cell Count as Predictor and High CD4 T Cell Intrinsic Apoptosis as Final Mechanism of Poor CD4 T Cell Recovery in Virologically Suppressed HIVâ€Infected Patients: Clinical Implications. Clinical Infectious Diseases, 2010, 50, 1300-1308.	5.8	133

#	Article	IF	Citations
145	HIV and Mature Dendritic Cells: Trojan Exosomes Riding the Trojan Horse?. PLoS Pathogens, 2010, 6, e1000740.	4.7	184
146	Could CD4 Capture by<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mtext>CD</mml:mtext><mml:msup><mml:mn mathvariant="bold">8</mml:mn><mml:mo mathvariant="bold">+</mml:mo></mml:msup></mml:mrow></mml:math>T Cells Play a Role in HIV Spreading?. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	10
147	CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. Aids, 2010, 24, 959-968.	2.2	114
148	Distribution of CD31 on CD4 T-Cells from Cord Blood, Peripheral Blood and Tonsil at Different Stages of Differentiation~!2009-11-24~!2009-12-24~!2010-03-05~!. The Open Immunology Journal, 2010, 3, 19-26.	1.5	5
149	Secretion of interferonâ€Î³ by human macrophages demonstrated at the singleâ€cell level after costimulation with interleukin (IL)â€12 plus ILâ€18. Immunology, 2009, 126, 386-393.	4.4	173
150	On the steps of cell-to-cell HIV transmission between CD4 T cells. Retrovirology, 2009, 6, 89.	2.0	38
151	Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood, 2009, 113, 2732-2741.	1.4	208
152	Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. Aids, 2009, 23, 183-188.	2.2	70
153	HIV transfer between CD4 T cells does not require LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope glycoprotein with CD4. Retrovirology, 2008, 5, 32.	2.0	46
154	HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells. Autophagy, 2008, 4, 998-1008.	9.1	123
155	Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. Journal of Antimicrobial Chemotherapy, 2007, 61, 400-404.	3.0	11
156	Maturation of Blood-Derived Dendritic Cells Enhances Human Immunodeficiency Virus Type 1 Capture and Transmission. Journal of Virology, 2007, 81, 7559-7570.	3.4	99
157	The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy. Aids, 2006, 20, 619-621.	2.2	28
158	Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10. Clinical and Experimental Immunology, 2006, 145, 535-544.	2.6	50
159	Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody. Antiviral Research, 2006, 69, 173-180.	4.1	27
160	Multiparametric Assay To Screen and Dissect the Mode of Action of Anti-Human Immunodeficiency Virus Envelope Drugs. Antimicrobial Agents and Chemotherapy, 2005, 49, 3926-3929.	3.2	10
161	Inhibition of Coreceptor-Independent Cell-to-Cell Human Immunodeficiency Virus Type 1 Transmission by a CD4-Immunoglobulin G2 Fusion Protein. Antimicrobial Agents and Chemotherapy, 2005, 49, 4296-4304.	3.2	22
162	R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. Journal of Leukocyte Biology, 2004, 76, 804-811.	3.3	51

#	Article	IF	Citations
163	Immunological and virological study of enfuvirtide-treated HIV-positive patients. Aids, 2004, 18, 1673-1682.	2.2	31
164	High Level of Coreceptor-independent HIV Transfer Induced by Contacts between Primary CD4 T Cells. Journal of Biological Chemistry, 2004, 279, 51305-51314.	3.4	89
165	Cell-Surface-Expressed HIV-1 Envelope Induces the Death of CD4 T Cells during GP41-Mediated Hemifusion-like Events. Virology, 2003, 305, 318-329.	2.4	70
166	CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Annals of Hematology, 2003, 82, 500-505.	1.8	63
167	Reduced fitness of HIV-1 resistant to CXCR4 antagonists. Antiviral Therapy, 2003, 8, 1-8.	1.0	10
168	Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death. Antiviral Therapy, 2003, 8, 155-61.	1.0	7
169	Anti-HIV-1 Activity of Enfuvirtide (T-20) by Inhibition of Bystander Cell Death. Antiviral Therapy, 2003, 8, 155-161.	1.0	25
170	Reduced Fitness of HIV-1 Resistant to Cxcr4 Antagonists. Antiviral Therapy, 2003, 8, 1-8.	1.0	51
171	Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+T Cells. AIDS Research and Human Retroviruses, 2002, 18, 27-38.	1.1	12
172	Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. Aids, 2002, 16, 2385-2390.	2.2	197
173	Anti-HIV activity of a novel aminoglycoside-arginine conjugate. Antiviral Research, 2002, 53, 1-8.	4.1	31
174	Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO Journal, 2002, 21, 4070-4080.	7.8	146
175	Interleukin-7 in Plasma Correlates with CD4 T-Cell Depletion and May Be Associated with Emergence of Syncytium-Inducing Variants in Human Immunodeficiency Virus Type 1-Positive Individuals. Journal of Virology, 2001, 75, 10319-10325.	3.4	127
176	CD4+ and CD8+ T Cell Death during Human Immunodeficiency Virus Infection in Vitro. Virology, 2001, 285, 356-365.	2.4	19
177	Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycinâ€“Associated Proteinâ€“Mediated P53 Phosphorylation. Journal of Experimental Medicine, 2001, 194, 1097-1110.	8.5	147
178	Comodulation of CXCR4 and CD26 in Human Lymphocytes. Journal of Biological Chemistry, 2001, 276, 19532-19539.	3.4	89
179	Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo. Aids, 2001, 15, 1890-1892.	2.2	15
180	Evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives. Transfusion, 2000, 40, 461-467.	1.6	11

#	Article	IF	Citations
181	The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. Antimicrobial Agents and Chemotherapy, 2000, 44, 51-56.	3.2	59
182	Anti-Human Immunodeficiency Virus Activity of Novel Aminoglycoside-Arginine Conjugates at Early Stages of Infection. AIDS Research and Human Retroviruses, 2000, 16, 627-634.	1.1	36
183	Apoptosis Control in Syncytia Induced by the HIV Type 1â€“Envelope Glycoprotein Complex. Journal of Experimental Medicine, 2000, 192, 1081-1092.	8.5	217
184	The HIV-1 gp120 inhibits the binding of adenosine deaminase to CD26 by a mechanism modulated by CD4 and CXCR4 expression. FEBS Letters, 2000, 477, 123-128.	2.8	32
185	Mitochondrial Control of Cell Death Induced by HIVâ€1â€Encoded Proteins. Annals of the New York Academy of Sciences, 2000, 926, 149-164.	3.8	76
186	The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. Aids, 1999, 13, 909-917.	2.2	74
187	Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. Aids, 1999, 13, 547-555.	2.2	25
188	Shift of Clinical Human Immunodeficiency Virus Type 1 Isolates from X4 to R5 and Prevention of Emergence of the Syncytium-Inducing Phenotype by Blockade of CXCR4. Journal of Virology, 1999, 73, 5577-5585.	3.4	90
189	Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunological Reviews, 1998, 161, 27-42.	6.0	158
190	Dipeptidyl-peptidase IV-beta. Further characterization and comparison to dipeptidyl-peptidase IV activity of CD26. FEBS Journal, 1998, 256, 369-378.	0.2	27
191	Ecto-adenosine deaminase: An ecto-enzyme and a costimulatory protein acting on a variety of cell surface receptors. , 1998, 45, 261-268.		12
192	Specific and Irreversible Cyclopeptide Inhibitors of Dipeptidyl Peptidase IV Activity of the T-Cell Activation Antigen CD26. Journal of Medicinal Chemistry, 1998, 41, 2100-2110.	6.4	14
193	Increased Rate of HIV-1 Entry and Its Cytopathic Effect in CD4+/CXCR4+T Cells Expressing Relatively High Levels of CD26. Experimental Cell Research, 1998, 241, 352-362.	2.6	22
194	Identification of V3 Loop-binding Proteins as Potential Receptors Implicated in the Binding of HIV Particles to CD4+Cells. Journal of Biological Chemistry, 1998, 273, 21988-21997.	3.4	66
195	Pseudopeptide TASP Inhibitors of HIV Entry Bind Specifically to a 95-kDa Cell Surface Protein. Journal of Biological Chemistry, 1997, 272, 7159-7166.	3.4	22
196	69-kDa and 100-kDa Isoforms of Interferon-Induced (2'-5')Oligoadenylate Synthetase Exhibit Differential Catalytic Parameters. FEBS Journal, 1997, 248, 558-566.	0.2	57
197	HIV-1 envelope glycoproteins-mediated apoptosis is regulated by CD4 dependent and independent mechanisms. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 47-60.	4.9	28
198	The Level of CD26 Determines the Rate of HIV Entry in a CD4+ T-Cell Line. Advances in Experimental Medicine and Biology, 1997, 421, 179-184.	1.6	1

#	Article	IF	Citations
199	HIV-1 Envelope gp120 and Viral Particles Block Adenosine Deaminase Binding to Human CD26. Advances in Experimental Medicine and Biology, 1997, 421, 185-192.	1.6	7
200	Further Characterization of DPP IV-Î², a Novel Cell Surface Expressed Protein with Dipeptidyl Peptidase Activity. Advances in Experimental Medicine and Biology, 1997, 421, 193-199.	1.6	4
201	Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells. Journal of Virology, 1997, 71, 8289-8298.	3.4	58
202	Specific Binding of Adenosine Deaminase but Not HIV-1 Transactivator Protein Tat to Human CD26. Experimental Cell Research, 1996, 225, 102-111.	2.6	28
203	Inhibition of HIV Infection by Pseudopeptides Blocking Viral Envelope Glycoprotein-Mediated Membrane Fusion and Cell Death. Virology, 1996, 218, 181-192.	2.4	38
204	HIV Envelope Glycoprotein-Induced Cell Killing by Apoptosis Is Enhanced with Increased Expression of CD26 in CD4+T Cells. Virology, 1996, 223, 318-330.	2.4	33
205	Dipeptidyl-Peptidase IV-beta, a Novel form of Cell-Surface-Expressed Protein with Dipeptidyl-Peptidase IV Activity. FEBS Journal, 1996, 239, 248-258.	0.2	49
206	Solubilization and molecular characterization of the nitrobenzylthioinosine binding sites from pig kidney brush-border membranes. Biochimica Et Biophysica Acta - Biomembranes, 1994, 1191, 94-102.	2.6	9
207	Adenine nucleotides and adenosine metabolism in pig kidney proximal tubule membranes. Journal of Cellular Physiology, 1993, 157, 77-83.	4.1	12
208	Characterization of adenosine receptors in brushâ€border membranes from pig kidney. British Journal of Pharmacology, 1992, 107, 671-678.	5.4	23
209	Adenosine metabolism in kidney slices under normoxic conditions. Journal of Cellular Physiology, 1990, 143, 344-351.	4.1	5
210	T-Follicular-Like CD8+ T Cell Responses in Chronic HIV Infection Are Associated With Virus Control and Antibody Isotype Switching to IgG. Frontiers in Immunology, 0, 13, .	4.8	1